Michael Shurin, MD, PhD
Associate Professor of Pathology

Dr. Shurin
Dr. Shurin is the Associate Director of the Division of Clinical Immunopathology.
Office Location:
S735, Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-648-9841
Lab Telephone: 412-648-9831
Fax: 412-648-8158
Email: shurinmr@upmc.edu

Clinical Expertise

Dr. Shurin’s clinical duties include the everyday evaluation of results of numerous blood tests, teaching Pathology residents and medical students, and dealing with different administrative issues at the Division of Clinical Immunopathology. Immunodiagnostic tests include a number of ELISA, RIA, IF, electrophoresis, Western blot tests for autoimmune, infectious, allergic and immunoproliferative diseases.

Research Expertise

Dr. Shurin’s research focuses on molecular and cellular interactions in the tumor microenvironment and, more specifically, on myeloid regulatory cell differentiation, function and interaction in the tumor immunoenvironment. Revealing both intrinsic (cells, cytokines, small molecules) and extrinsic (environmental nanomaterials, infectious agents) regulators of immune cells in cancer is crucial for improving cancer treatment and designing novel highly efficient approaches to cancer immunotherapy.


Diplomat, American Board of Medical Laboratory Immunology (ABMLI)


Clinical immunology and Immunopathology

Selected Publications

View Dr. Shurin's publications on PubMed

Kaneno R., Shurin G.V., Kaneno F.M., Naiditch H., Luo J., Shurin M.R. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell. Oncol., 34(2):97-106, 2011.

Shurin M.R., Naiditch H., Zhong H., Shurin G.V. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol. Ther., 11(11):988-992, 2011.

Naiditch H., Shurin M.R., Shurin G.V. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunol. Res., 50(2-3):276-285, 2011.

Tkach A.V., Shurin G.V., Shurin M.R., Kisin E.R., Murray A.R., Young S-H., Star A., Fadeel B., Kagan V.E., Shvedova A.A. Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure. ACS Nano, 5(7):5755-5762, 2011.

Sevko A., Kremer V., Falk C., Umansky L., Shurin M.R., Shurin G.V., Umansky V. Application of paclitaxel in low noncytotoxic doses supports vaccination with melanoma antigens in mice. J. Immunotoxicol., 2012, in press.

Michels T., Shurin G.V., Naiditch H., Sevko A., Umansky V., Shurin M.R. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol., 2012, in press. Shurin M.R. Cancer as an immune-mediated disease. Editorial. ImmunoTargets and Therapy, 2012 (1):1-6, 2012.

Shvedova A.A., Tkach A.V., Kisin E.R., Khaliullin T., Stanley S., Gutkin D.W., Star A., Chen Y., Shurin G.V., Kagan V.E., Shurin M.R. Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. Small, in press, 2013.

Tkach A., Yanamala N., Stanley S., Shurin M., Shurin G., Kisin E., Murray A., Pareso S., Khaliullin T., Kotchey G., Castranova V., Mathur S., Fadeel B., Star A., Kagan V., Shvedova A. Graphene oxide, but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells. Small, in press, 2013.

Ismail N., Shurin M.R. Cancer and infection: friends or foes? Editorial. Future Oncology, 8(9):1061-1064, 2012.

Shurin M.R. Dual role of immunomodulation by anticancer chemotherapy. Nature Med., 19(1):20-22, 2013.

Sevko A., Michels T., Vrohlings M., Ramacher M., Umansky L., Beckhove P., Kato M., Shurin G.V., Shurin M.R., Umansky V. Anti-tumor effect of paclitaxel is mediated by inhibition of MDSCs and chronic inflammation in the spontaneous melanoma model. J. Immunol., 190(5):2464-71, 2013.

Ustinova E.E., Shurin G.V., Paris J., Gutkin D.W., Shurin M.R. The role of TLR4 signaling in the paclitaxel effects on neuronal growth in vitro. PLoS ONE, 8(2):e56886, 2013.

Di Y.P., , Tkach A.V., Yanamala N., Stanley S., Gao S., Shurin M.R., Kisin E.R., Kagan V.E., Shvedova A. Dual acute pro-inflammatory and anti-fibrotic pulmonary effects of SPLUNC1 after exposure to carbon nanotubes. Amer. J. Respir. Cell Mol. Biol., 2013, in press.


Kotlan B., Umansky V., Malyguine A.M., Marincola F.M., Shurin M.R. Conference Scene: Immunotherapy reaches new milestones in cancer eradication. Immunotherapy, 3(10):1131-1137, 2011.

Umansky V., Malyguine A., Kotlan B., Aptsiauri N., Shurin M.R. From cell regulation to patient survival: 2nd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting. Cancer Immunol. Immunother., 61(2): 223–230, 2012 (NIHMS 363339).

Malyguine A., Umansky V., Kotlan B., Aptsiauri N., Shurin M.R. Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward. J. Immunotoxicol., 9(3):231-235, 2012.

Malyguine A., Strobl S., Shurin M.R. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol. Immunother., 61(2):239-47, 2012.

Shurin G.V., Ouellette C.E., Shurin M.R. Regulatory dendritic cells in the tumor immuno-environment. Cancer Immunol. Immunother., 61(2):223-30, 2012.

Shurin M.R., Naiditch H., Gutkin D.W., Umansky V., Shurin G.V. ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents. Curr. Med. Chem., 19(12):1792-1803, 2012.

Ma Y., Shurin G.V., Gutkin D.W., Shurin M.R. Tumor-associated regulatory dendritic cells. Seminars in Cancer Biology, 22(4):298-306, 2012.

Malyguine A., Strobl S., Dunham K., Shurin M., Sayers T. ELISPOT assay for monitoring CTL activity in cancer vaccine clinical trials. Cells, 1(2), 111-126, 2012.

Ma Y., Shurin G.V., Zhu P., Shurin M.R. Dendritic cells in the cancer microenvironment. Journal of Cancer, ;4(1):36-44, 2013.

Malyguine A., Umansky V., Shurin M.R. Role of the immunological environment in cancer initiation, development and progression. In: “The Tumor Immunoenvironment”, M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp.1-12, 2013. Shurin M.R., Umansky V. Chemoimmunomodulation: Focus on myeloid regulatory cells. In: “The Tumor Immunoenvironment”, M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp. 603-619, 2013.

Malyguine A., Dunham K., Sayers T., Shurin M.R. Evaluation of the tumor immunoenvironment in clinical trials. In: “The Tumor Immunoenvironment”, M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp. 695-706, 2013.

Zhu P., Segal Y.V., Shurin G.V., Shurin M.R. Analysis of myeloid-derived suppressor cells in patients with cancer. In: “The Tumor Immunoenvironment”, M.R.Shurin, V.Umansky, A.Malyguine (Eds), Springer Publ., N.Y., pp.707-723, 2013.

Shurin G.V., Ma Y., Shurin M.R. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenvironment, 2013, in press.


The Tumor ImmunoEnvironment”, M.R.Shurin, V.Umansky, A.Malyguine (Eds), 745 pages. Springer Publ., N.Y., 2013. (ISBN 978-94-007-6216-6)